CCXI Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 8.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
ChemoCentryx Insider Trading History Chart
This chart shows the insider buying and selling history at ChemoCentryx by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
ChemoCentryx Share Price & Price History
Current Price: $51.99
Price Change: +0.30 (1.20%)
As of 11/2/2022 01:00 AM ET
ChemoCentryx Insider Trading History
ChemoCentryx Institutional Trading History
Data available starting January 2016
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Read More on ChemoCentryx
Today's Range
Now: $51.99
52 Week Range
Now: $51.99
Volume
113 shs
Average Volume
1,681,906 shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.22